Status:
COMPLETED
Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
CoVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Novel corona virus (SARS-CoV-2) epidemic which stared from Wuhan in China is now a well established pandemic worldwide. After Italy, Spain, Germany, United Kingdom and USA, India is at the edge of bec...
Detailed Description
Background and rational of the study: Novel corona virus (SARS-CoV-2) epidemic which stared from Wuhan in China is now a well established pandemic worldwide affecting more than 3 lakh people with mor...
Eligibility Criteria
Inclusion
- Inclusion:
- Asymptomatic individuals who have undertaken International travel in last 2 weeks
- Asymptomatic individual with direct contact with laboratory confirmed cases
- Exclusion:
- Symptomatic individual
- Health care worker
- Individual who will not give consent for HCQ prophylaxis and patients with contraindication for HCQ therapy like, hypersensitivity to HCQ or 4-aminoquinolone derivatives, patients with known retionopathy, cardiac arrhythmia, G6PD deficiency, psoriasis and pregnancy will be directly included in the control groups.
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT04408456
Start Date
March 1 2020
End Date
July 31 2020
Last Update
August 4 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Post Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh, India, 160012
2
Post Graduate Institute of Medical Education and Research
Chandigarh, India, 160012